Chimerix Appoints Heather Knight-Trent, PharmD, as Vice President of Regulatory Affairs
September 12 2017 - 7:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company committed to
discovering, developing and commercializing medicines that improve
outcomes for immunocompromised patients, today announced the
appointment of Heather Knight-Trent, PharmD, as Vice President of
Regulatory Affairs. Dr. Knight-Trent brings more than 15 years of
pharmaceutical regulatory experience to Chimerix and will be
responsible for managing all U.S. and global regulatory matters for
the Company, including strategy, filings and interactions with
regulatory authorities.
“We are delighted to have Heather join the Chimerix team during
this critical time in the Company’s growth,” said M. Michelle
Berrey, MD, MPH, President and CEO of Chimerix. “Her extensive
pharmaceutical regulatory experience and scientific background will
be valuable as we continue to advance brincidofovir’s development
and progress earlier stage molecules in our pipeline in the years
ahead.”
“I am thrilled to join the Chimerix leadership team at this
exciting time for the Company,” said Dr. Knight-Trent. “There is a
great opportunity for brincidofovir to potentially prevent and
treat a broad range of life-threatening viral infections in
immunocompromised individuals, and I look forward to being part of
the team committed to getting brincidofovir to patients,” said Dr.
Knight-Trent.
Dr. Knight-Trent was previously executive director of regulatory
affairs at Hurley Consulting Associates, where she was responsible
for regulatory strategy and implementation for multiple clients.
She was previously at Bristol Myers Squibb for ten years in roles
both in the U.S. and Europe, most recently as the director of
global regulatory, safety and biometrics business operations. In
this role Dr. Knight-Trent supported the vice presidents of global
regulatory strategy for all therapeutic areas on resourcing,
budget, group capabilities and continuous improvement projects. She
also held positions in regulatory affairs at Zymogenetics (acquired
by Bristol-Myers Squibb) in Seattle, Washington and at Hoffmann-La
Roche, Inc., in Nutley, New Jersey.
Dr. Knight-Trent holds a bachelor’s degree in biology and a
doctor of pharmacy degree from West Virginia University. In 2000
and 2001, she was a Rutgers Industrial Pharmacy Post-Doctoral
Fellow with Hoffmann-La Roche, Inc., and FDA CDER’s oncology
division. Dr. Knight-Trent is a registered pharmacist in West
Virginia and she is a member of the West Virginia University School
of Pharmacy Leadership Council.
About ChimerixChimerix is a
biopharmaceutical company dedicated to discovering, developing and
commercializing medicines that improve outcomes for
immunocompromised patients. Chimerix's proprietary lipid
conjugate technology has produced brincidofovir (BCV, CMX001);
CMX157, which was licensed to ContraVir Pharmaceuticals; and
earlier-stage compounds. Chimerix recently announced a new clinical
candidate, CMX521, for the treatment and/or prevention of
norovirus. For further information, please
visit Chimerix's website, www.chimerix.com.
Forward-Looking Statements This press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 that are subject
to risks, uncertainties and other factors, including the
possibility that there may not be a viable continued development
path for brincidofovir, that FDA and other regulatory
authorities may not approve brincidofovir or brincidofovir-based
regimens, that CMX521 may not demonstrate expected activity against
norovirus, and that marketing approvals, if granted, may have
significant limitations on their use. As a result, brincidofovir
may never be successfully commercialized. In
addition, Chimerix may be unable to file for regulatory
approval for brincidofovir with other regulatory authorities. These
risks, uncertainties and other factors could cause actual results
to differ materially from those expressed or implied by such
forward-looking statements. Risks are described more fully in the
Company's filings with the Securities and Exchange Commission,
including without limitation the Company's most recent Quarterly
Report on Form 10-Q and other documents subsequently filed with or
furnished to the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. The Company undertakes
no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were
made.
CONTACT:Investor
Relations:ir@chimerix.comorWill O’ConnorStern Investor
RelationsWill@sternir.com212-362-1200
Media:
Becky VonsiatskyW2O
Groupbvonsiatsky@w2ogroup.com413-478-2003
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024